all

The National Lipid Association (NLA) endorses the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, published by the American College of Cardiology on April 1 in the Journal of the American College of Cardiology. Click here to view the document.

By Batya Swift Yasgur, MA, LMSW

In February of 2016, the National Lipid Association (NLA) released its Annual Summary of Clinical Lipidology, which is an update to Parts 1 and 2 of the NLA's “Recommendations for Patient-Centered Management of Dyslipidemia,” both published in 2015. The summary is unique in that it contains both updated content and a novel format. To shed further light on the changes in the new summary, MPR spoke to Harold E. Bays, MD, who was the lead author. 

By Carol Kirkpatrick, PhD, RDN, LDN, CLS, FNLA; Geeta Sikand, MA, RDN, FAND, CLS, CDE, FNLA; Ralph LaForge, MSc, CLS, FNLA

In September, the National Lipid Association released its new Recommendations for Patient-Centered for Dyslipidemia Management – Part 2. These recommendations include a thorough review of the lifestyle therapies — nutrition and physical activity — that promote atherosclerotic CVD risk reduction through lowering atherogenic cholesterol and other atherosclerotic CVD risk factors.

Targets of lifestyle therapies